Somewhat Positive News Coverage Somewhat Unlikely to Impact Illumina (ILMN) Stock Price

News stories about Illumina (NASDAQ:ILMN) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Illumina earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the life sciences company an impact score of 45.7219564086932 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

Illumina (NASDAQ ILMN) traded up $0.07 on Friday, reaching $229.20. 701,696 shares of the company’s stock were exchanged, compared to its average volume of 1,100,000. Illumina has a 12 month low of $158.02 and a 12 month high of $248.97. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43. The stock has a market cap of $33,460.00, a price-to-earnings ratio of 38.59, a PEG ratio of 2.95 and a beta of 0.92.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The company had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. During the same period last year, the firm posted $0.85 EPS. Illumina’s revenue for the quarter was up 25.7% compared to the same quarter last year. equities research analysts anticipate that Illumina will post 4.59 EPS for the current fiscal year.

ILMN has been the subject of several research analyst reports. Deutsche Bank raised shares of Illumina from a “hold” rating to a “buy” rating and decreased their price objective for the company from $195.00 to $160.00 in a research report on Monday, October 23rd. Janney Montgomery Scott raised shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. Robert W. Baird raised shares of Illumina from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $184.00 to $228.00 in a research report on Wednesday, October 25th. Wells Fargo & Co reaffirmed a “market perform” rating and issued a $205.00 price objective (up from $200.00) on shares of Illumina in a research report on Wednesday, October 25th. Finally, Bank of America increased their price objective on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. Illumina presently has a consensus rating of “Buy” and an average target price of $241.39.

In other news, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $216.87, for a total transaction of $433,740.00. Following the sale, the executive vice president now owns 27,952 shares of the company’s stock, valued at approximately $6,061,950.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 1,610 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $221.45, for a total transaction of $356,534.50. Following the sale, the senior vice president now directly owns 5,581 shares in the company, valued at approximately $1,235,912.45. The disclosure for this sale can be found here. Insiders have sold a total of 114,440 shares of company stock valued at $25,318,904 over the last three months. 0.89% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Illumina (ILMN) Stock Price” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/16/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-illumina-ilmn-stock-price.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply